Intercept Pharmaceuticals 관리
관리 기준 확인 3/4
Intercept Pharmaceuticals CEO는 Jerry Durso, Jan2021 에 임명되었습니다 의 임기는 2.83 년입니다. 총 연간 보상은 $ 4.46M, 16% 로 구성됩니다. 16% 급여 및 84% 보너스(회사 주식 및 옵션 포함). 는 $ 984.47K 가치에 해당하는 회사 주식의 0.12% 직접 소유합니다. 984.47K. 경영진과 이사회의 평균 재임 기간은 각각 2.7 년과 8.7 년입니다.
주요 정보
Jerry Durso
최고 경영자
US$4.5m
총 보상
| CEO 급여 비율 | 16.0% |
| CEO 임기 | 2.8yrs |
| CEO 소유권 | 0.1% |
| 경영진 평균 재임 기간 | 2.7yrs |
| 이사회 평균 재임 기간 | 8.7yrs |
최근 관리 업데이트
Recent updates
Revenues Working Against Intercept Pharmaceuticals, Inc.'s (NASDAQ:ICPT) Share Price Following 25% Dive
Jun 08
Intercept Pharmaceuticals (NASDAQ:ICPT) Has Debt But No Earnings; Should You Worry?
Apr 11Health Check: How Prudently Does Intercept Pharmaceuticals (NASDAQ:ICPT) Use Debt?
Dec 20Intercept touts Ocaliva benefit in transplant-free survival in liver disease type
Sep 20Intercept cuts debt further with deal to exchange convertible notes
Sep 02Intercept reduces debt with repurchases of $327.9M convertible notes
Aug 19Intercept Pharmaceuticals: Too Risky To Buy At This Stage
Aug 13Intercept Pharma Q2 2022 Earnings Preview
Aug 02Intercept to resubmit for FDA approval of NASH candidate after new analysis
Jul 07Intercept: Increase Of Ocaliva Sales And A Few Catalysts
May 23Need To Know: Analysts Are Much More Bullish On Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)
May 10Intercept: Opportunity To Buy On Potential NDA Resubmission Of Ocaliva For NASH
Mar 05Intercept names Andrew Saik as chief financial officer
Jun 07Intercept Pharmaceuticals slides as FDA restricts Ocaliva use
May 26CEO 보상 분석
| 날짜 | 총 보상 | 급여 | 회사 수익 |
|---|---|---|---|
| Sep 30 2023 | n/a | n/a | -US$57m |
| Jun 30 2023 | n/a | n/a | -US$159m |
| Mar 31 2023 | n/a | n/a | -US$173m |
| Dec 31 2022 | US$4m | US$715k | -US$175m |
| Sep 30 2022 | n/a | n/a | -US$202m |
| Jun 30 2022 | n/a | n/a | -US$115m |
| Mar 31 2022 | n/a | n/a | -US$120m |
| Dec 31 2021 | US$8m | US$691k | -US$136m |
| Sep 30 2021 | n/a | n/a | -US$144m |
| Jun 30 2021 | n/a | n/a | -US$193m |
| Mar 31 2021 | n/a | n/a | -US$231m |
| Dec 31 2020 | US$4m | US$600k | -US$273m |
| Sep 30 2020 | n/a | n/a | -US$321m |
| Jun 30 2020 | n/a | n/a | -US$339m |
| Mar 31 2020 | n/a | n/a | -US$347m |
| Dec 31 2019 | US$4m | US$573k | -US$345m |
| Sep 30 2019 | n/a | n/a | -US$335m |
| Jun 30 2019 | n/a | n/a | -US$314m |
| Mar 31 2019 | n/a | n/a | -US$318m |
| Dec 31 2018 | US$3m | US$541k | -US$309m |
| Sep 30 2018 | n/a | n/a | -US$333m |
| Jun 30 2018 | n/a | n/a | -US$341m |
| Mar 31 2018 | n/a | n/a | -US$352m |
| Dec 31 2017 | US$4m | US$441k | -US$360m |
보상 대 시장: Jerry 의 총 보상 ($USD 4.46M )은 US 시장( $USD 3.15M ).
보상과 수익: Jerry 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.
CEO
Jerry Durso (55 yo)
2.8yrs
테뉴어
US$4,455,463
보상
Mr. Jerome B. Durso, also known as Jerry, has been President and Chief Executive Officer of Intercept Pharmaceuticals, Inc. since January 1, 2021 and serves as its Director since May 27, 2021. Mr. Durso se...
리더십 팀
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| President | 2.8yrs | US$4.46m | 0.12% $ 984.5k | |
| Chief Financial Officer | 2.4yrs | US$1.39m | 0.055% $ 437.4k | |
| General Counsel | 2.8yrs | US$1.31m | 0.13% $ 1.1m | |
| Executive VP & Chief Commercial Officer | 2.8yrs | US$1.34m | 0.040% $ 317.4k | |
| President of Research & Development and Chief Medical Officer | 2.4yrs | US$1.61m | 0.068% $ 538.6k | |
| Chief Accounting Officer & Treasurer | 2.7yrs | US$856.23k | 0.061% $ 483.6k | |
| Executive Director of Global Investor Relations | 1.9yrs | 데이터 없음 | 데이터 없음 | |
| Chief Human Resources Officer | 6.5yrs | US$1.91m | 0.036% $ 285.7k | |
| Founder | 2.8yrs | US$6.43m | 1.48% $ 11.8m | |
| Senior Vice President of Regulatory Affairs | no data | 데이터 없음 | 데이터 없음 | |
| Chief Quality Officer & SVP of Technical Operations | less than a year | 데이터 없음 | 데이터 없음 | |
| Senior Vice President of Corporate Affairs | less than a year | 데이터 없음 | 데이터 없음 |
2.7yrs
평균 재임 기간
55yo
평균 연령
경험이 풍부한 관리: ICPT 의 관리팀은 경험 ( 2.7 년 평균 재직 기간)으로 간주됩니다.
이사회 구성원
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| President | 2.5yrs | US$4.46m | 0.12% $ 984.5k | |
| Founder | 21.8yrs | US$6.43m | 1.48% $ 11.8m | |
| Independent Chairman | 7.3yrs | US$327.39k | 0.056% $ 447.4k | |
| Independent Director | 9.8yrs | US$332.39k | 0.056% $ 445.5k | |
| Independent Director | 9.3yrs | US$327.39k | 0.061% $ 484.3k | |
| Independent Director | 11.1yrs | US$317.39k | 0.091% $ 719.8k | |
| Lead Independent Director | 8yrs | US$337.39k | 0.057% $ 449.2k | |
| Member of the Scientific Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Member of the Scientific Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Member of the Scientific Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Member of the Scientific Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Independent Director | 7.3yrs | US$322.39k | 0.059% $ 469.7k |
8.7yrs
평균 재임 기간
62yo
평균 연령
경험이 풍부한 이사회: ICPT 의 이사회는 경험(평균 재직 기간 8.7 년)으로 간주됩니다.